Alfacalcidol CAS 41294-56-8

Introduction：Basic information about Alfacalcidol CAS 41294-56-8, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Alfacalcidol Basic information

• Product Name: Alfacalcidol
• Synonyms: 5-[2E-[(3aS)-1R-[1R,5-dimethylhexyl]octahydro-7aR-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1R,3R-cyclohexanediol;Alfacalcidol/1α-Hydroxyvitamin D3;Alfacalcidol / 1α-Hydroxycholecalciferol;Vitamin D?, 1α-Hydroxy-;7,10(19)-triene-1,3-diol,(1-alpha,3-beta,5z,7e)-10-secocholesta-5;ALFACALCIDOL;ALPHACALCIDOL;1-HYDROXYCHOLECALCIFEROL
• CAS: 41294-56-8
• MF: C27H44O2
• MW: 400.64
• EINECS: 255-297-1
• Product Categories: Inhibitors;Vitamin D3 analogs;API;Intermediates & Fine Chemicals;Pharmaceuticals;Miscellaneous Compounds;41294-56-8
• Mol File: 41294-56-8.mol

Alfacalcidol Chemical Properties

• Melting point: 134-136°C
• Boiling point: 531.5±50.0 °C(Predicted)
• density: 1.01±0.1 g/cm3(Predicted)
• storage temp.: −20°C
• solubility: Practically insoluble in water, freely soluble in ethanol (96 per cent), soluble in fatty oils.
• form: White crystalline solid
• pka: 14.43±0.40(Predicted)
• color: White to Almost white
• biological source: synthetic
• λmax: 264nm(Diethyl ether)(lit.)
• Merck: 14,4819
• Stability: Light Sensitive
• InChIKey: OFHCOWSQAMBJIW-GITLSTMWSA-N
• SMILES: [C@@H]1(O)CC(=C/C=C2\CCC[C@@]3(C)[C@@]\2([H])CC[C@@H]3[C@H](C)CCCC(C)C)C(=C)[C@H](O)C1
• CAS DataBase Reference: 41294-56-8(CAS DataBase Reference)
• EPA Substance Registry System: Alphacalcidol (41294-56-8)

Safety Information

• Hazard Codes: T+,Xi
• Risk Statements: 26/27/28-36/37/38
• Safety Statements: 28-36/37-45-36-26
• RIDADR: UN 2811 6.1/PG 1
• WGK Germany: 3
• RTECS: VS2851000
• F: 8-10
• HazardClass: 6.1(a)
• PackingGroup: I
• HS Code: 29361000
• Storage Class: 6.1A - Combustible acute toxic Cat. 1 and 2 very toxic hazardous materials
• Hazard Classifications: Acute Tox. 1 Oral

Alfacalcidol Usage And Synthesis

Description

Alfacalcidol(41294-56-8) is a vitamin D analog. It is important for the regulation of the bone metabolism. Alfacaldidol is a regulator of calcium and phosphorus metabolism, which helps calcium and phosphorus to be absorbed more effectively in the intestines. Thus, alfacalcidol is used to treat renal (kidney) bone diseases, rickets, osteoporosis, and patients with high or low activity of the parathyroid gland. Also, it is used to maintain normal calcium levels within the body. Alfacalcidol has significant effects on the immune system, including regulatory T cells. Alfacalcidol is furthermore used as a poultry feed additive to prevent tibial dyschondroplasia and increases phytate bioavailability.

Physical and Chemical Properties

White crystal or crystalline powder, insoluble in water and hexane, soluble in methanol, ethanol, chloroform, methylene chloride, acetone or ether. Perishable in case of air and light .

Pharmacological effects

Alfacalcidol(41294-56-8) is quickly converted by the liver into 1,25-dihydroxyvitamin D3, regulates calcium balance in the body, because of the enhancing of 1,25-dihydroxyvitamin D3 levels in vivo circulating , thereby increases the calcium and phosphorus intestinal absorption, promotes bone mineralization, decreases parathyroid hormone levels in plasma and reduces calcium resorption, relieves bone, muscle pain and improves osteoporosis and menopause, aging and steroid-induced intestinal related calcium malabsorption.
Alfacalcidol increases the intestinal and renal tubular reabsorption of calcium and inhibit parathyroid hyperplasia, reduces parathyroid hormone synthesis and release, inhibits bone resorption. Promotes collagen and bone matrix protein synthesis.Regulates Calcium metabolism of muscles , promotes muscle cells differentiation, enhances muscle strength, increases neuromuscular coordination, tends to reduce falls. Suitable for the treatment of rickets and osteomalacia, renal osteodystrophy, osteoporosis and hypoparathyroidism. Youth are limited to young people with idiopathic osteoporosis and glucocorticoid-induced osteoporosis too.
The above information is edited by the chemicalbook of Tian Ye.

Pharmacodynamics

This product after oral administration, is rapidly absorbed into the bloodstream from the gut, 25-hydroxy enzyme of the liver microsomal make 25-hydroxy of side chain compound to generate 1α, 25-(OH) 2D3, distributed in the intestine and bone and other target tissues, upon binding to the receptor, it can promote intestinal absorption of calcium, causing a series of physiological activities, such as bone salt dissolving and bone formation . Rats removed of the kidney and rats deficient in vitamin D, are given this product experiments, which shows that the level of promoting intestinal absorption of calcium, elevates serum calcium.Due to renal completely removed in rats removed of the kidney , the majority of bone resorption and bone-like cavity layer, low-calcified layer next layer increases, give this product 30d to experiment, the bone freshmen is observed. Therefore alfacalcidol promotes bone formation. Elderly patients with osteoporosis given this product ,iliac bone biopsy is performed by electronic and optical microscope to find that active osteoblasts, osteocytes, bone calcification small chamber increases, improves bone tissue.

Indications

Symptoms alfacalcidol can be used to improve chronic renal insufficiency, hypoparathyroidism, vitamin D-dependent rickets, a softening of bone disease caused by vitamin D metabolism, such as hypocalcemia, hand, foot cramps, pain , bone disease and osteoporosis embolism.

Instructions

For osteoporosis, oral: initial amount of 0.5μg/d, maintenance dose of 0.25~0.50μg, qd.
Dialysis patients with chronic hypocalcemia, 0.5~3.0μg/d, divided 2 to 3 times daily.
Hypoparathyroidism, 0.25~3.00μg/d, divided 2 to 3 times daily.
Renal bone atrophy, the next day 0.25~3.00μg, divided 2 to 3 times daily.
Vitamin D-dependent rickets, 1μg/d, divided 2 to 3 times daily.
Familial hypophosphatemia, 2μg/d, divided 2 to 3 times daily.

Adverse reactions

Small amount alone is usually no more adverse reactions, long-term large doses of medication or in combination with calcium can cause hypercalcemia and hypercalciuria.patients in Long-term high doses and patients with renal impairment may be nausea, loss of appetite, dizziness, skin itching, rash, constipation, anorexia, vomiting, abdominal pain, high calcium signs ,it can be restored to normal after treatment. Vitamin D and its analogues allergies, hypercalcemia, vitamin D poisoning signs patients are banned. Early medication serum calcium levels should be determined weekly, when a stable dose, they are measured every 2 to 4 weeks, especially renal dysfunction serum calcium levels should be measured regularly. when hypercalcemia occurs, It Shall be discontinued and deal with hypercalcemia. After serum calcium returns to normal , the dose is dministered half of the last dose. Alfacalcidol combination with calcium can cause elevated serum calcium, when it combined with thiazide diuretics can cause the danger of hypercalcemia . When treated with digitalis drugs, care should be taken to develop the amount of this drug.The amount of Alfacalcidol should be increased when combined with barbiturates, anticonvulsants .

Precautions

If hypercalcemia occurs,it should be stopped taking until serum calcium returns to normal (about a week), and then press the last half dose administration. patients have Vitamin D symptoms or known allergy to vitamin D and its analogues is unfit for use. Patients Should avoid taking vitamin D drugs at the same time, so as not to cause vitamin D intoxication.

Drug Interactions

Using Alfacalcidol and magnesium formulation (magnesium oxide, magnesium carbonate, etc.) sometimes causes hypermagnesemia.
Using Alfacalcidol and Cardiac preparations may cause cardiac arrhythmia.
Using Alfacalcidol and vitamin D and its derivatives (calcitriol) , it is possible to cause hypercalcemia.
Using Alfacalcidol and calcium , Thiazide diuretics, digitalis drugs , can cause hypercalcemia.
And barbiturates, anti-seizure drugs may reduce the efficacy of the drug.
Gastrointestinal absorption inhibitors can reduce the absorption of the drug.
Combination with large doseas of Phosphorus compounds, can induce hyperphosphatemia.
When Alfacalcidol and calcium preparations (calcium lactate, calcium carbonate, etc.) are used together, there may be hypercalcemia.

Uses

For the treatment of osteoporosis, vitamin D-dependent rickets and osteomalacia

Referrence

1. https://en.wikipedia.org/wiki/Alfacalcidol
2. https://www.drugbank.ca/drugs/DB01436
3. http://www.mhra.gov.uk
4. JD Ringe, H Faber, P Fahramand, E Schacht, Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis, J. Rheumatol. Suppl., 2005, vol. 76, 33-40 

Chemical Properties

White Solid

Originator

One-Alpha ,Leo ,UK ,1978

Uses

A synthetic analog of Calcitiol (the hormonal form of vitamin D3), which shows identical potency with respect to stimulation of intestinal calcium absorption and bone mineral mobilization. Vitamin D source

Definition

ChEBI: A member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in reglation of the calcium balance and the bone metabolism.

Manufacturing Process

1. Preparation of 1,4-cyclized adduct of cholesta-1,5,7-trien-β-ol and 4-phenyl-1,2,4-triazoline-3,5-dione: a solution of 400 mg of cholesta-1,5-7-trien-3β-ol in 30 ml of tetrahydrofuran is cooled with ice, and 190 mg of 4-phenyl-1,2,4-triazoline-3,5-dione is added little by little to the solution underagitation. The mixture is agitated at room temperature for 1 hour and thesolvent is distilled under reduced pressure. The residue is purified bychromatography using a column packed with silica gel. Fractions eluted withether-hexane (7:3 v/v) are collected and recrystallization from ether gives550 mg of a 1,4-cyclized adduct of cholesta-1,5,7-trien-3β-ol and 4-phenyl-1,2,4-triazoline-3,5-dione having a melting point of 178°C to 182°C.
2. Preparation of 1,4-cyclized adduct of cholesta-5,7-dien-3β-ol-1α-epoxideand 4-phenyl-1,2,4-triazoline-3,5-dione: 1.25 g of the 1,4-cyclized adduct ofcholesta-1,5,7-trien-3β-ol and 4-phenyl-1,2,4-triazoline-3,5-dione is dissolvedin 50 ml of chloroform, and 560 mg of m-chloroperbenzoic acid is added tothe solution. The mixture is agitated for 20 hours at room temperature, and200 mg of m-chloroperbenzoic acid is further added and the mixture isagitated again for 20 hours. The reaction mixture liquid is diluted withchloroform, washed with a 10% aqueous solution of potassium carbonate anddried with magnesium sulfate. Then, the solvent is distilled under reducedpressure. The residue is purified by silica gel chromatography, and firsteffluent fractions eluted with ether are collected, and recrystallization frommethanol gives 680 g of a crystal melting at 172°C to 173°C. The secondether effluent fractions are collected, and recrystallization from methanol gives400 mg of a 1,4-cyclized adduct of cholesta-5,7-dien-3β-ol-1α,2α-epoxide and4-phenyl-1,2,4-triazoline-3,5-dione having a melting point of 152°C to 154°C.
3. Preparation of cholesta-5,7-diene-1α,3β-diol: a solution of 500 mg of the1,4-cyclized adduct of cholesta-5,7-dien-3β-ol-1α,2α-epoxide and 4-phenyl-1,2,4-triazoline-3,5-dione in 40 ml of tetrahydrofuran is added dropwise underagitation to a solution of 600 mg of lithium aluminum hydride in 30 ml of THF.Then, the reaction mixture liquid is gently refluxed and boiled for 1 hour andcooled, and a saturated aqueous solution of sodium sulfate is added to thereaction mixture to decompose excessive lithium aluminum hydride. Theorganic solvent layer is separated and dried, and the solvent is distilled. The residue is purified by chromatography using a column packed with silica gel.Fractions eluted with ether-hexane (7:3 v/v) are collected, andrecrystallization from the methanol gives 400 mg of cholesta-5,7-diene-1α,3β-diol.
4. Preparation of 1α,3β-dihydroxyprovitamin D3: a solution of 25 mg ofcholesta-5,7-diene-1α,3β-diol in 650 ml of ether is subjected to radiation ofultraviolet rays for 14 minutes in an argon gas atmosphere by passing itthrough a Vycor filter using a 200-W high pressure mercury lamp (Model654A-36 manufactured by Hanobia). The solvent is distilled at roomtemperature under reduced pressure. This operation is repeated twice, and 50mg of the so obtained crude product is fractionated by chromatography usinga column packed with 20 g of Sephadex LH-20. The first effluent fractionseluted with chloroform-hexane (65:35 v/v) give 13.5 mg of oily 1α,3β-dihydroxyprovitamin D3. The composition exhibits a maximum ultravioletabsorption at 260 nm in an ether solution.
5. Preparation of 1α-hydroxycholecalciferol: a solution of 13.5 mg of 1α,3β-dihydroxyprovitamin D3 in 200 mi of ether is allowed to stand still in the darkat room temperature in an argon gas atmosphere for 2 weeks. During thisperiod, the position of the maximum ultraviolet absorption is shifted from 260nm to 264 nm, and the absorption intensity becomes 1.6 times as high as theoriginal intensity. The solvent is distilled at room temperature under reducedpressure, and the residue is purified by chromatography using a columnpacked with 10 g of Sephadex LH-20. The fractions eluted with chloroformhexane(65:35 v/v) give 6.5 mg of oily 1α-hydroxycholecalciferol.

Therapeutic Function

Calcium regulator, Vitamin

General Description

Has biological properties similar to 1α-Hydroxyvitamin D₂ (Cat. No. 679100). Converted to active Calcitriol (1α,25-Dihydroxyvitamin D₃; Cat. No. 679101) in vivo. Inhibits the formation of nephrocalcinosis in streptozotocin-induced diabetic rats fed on low zinc diets.

Biological Activity

Synthetic vitamin D3 analog th at is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

Clinical Use

Vitamin D analogue:
Increase serum calcium levels
Suppression of PTH production

Drug interactions

Potentially hazardous interactions with other drugs
Carbamazepine, fosphenytoin, phenytoin, phenobarbital and primidone may increase metabolism of alfacalcidol, necessitating larger doses than normal to produce the desired effect.

Metabolism

Alfacalcidol is hydroxylated in the liver by the enzyme vitamin D 25-hydroxylase to form the active 1,25-dihydroxycolecalciferol (calcitriol). Calcitriol is inactivated in both the kidney and the intestine, through the formation of a number of intermediates including the formation of the 1,24,25-trihydroxy derivatives. Vitamin D compounds and their metabolites are excreted mainly in the bile and faeces with only small amounts appearing in urine; there is some enterohepatic recycling but it is considered to have a negligible contribution to vitamin D status.

Alfacalcidol Preparation Products And Raw materials

• Raw materials: Lithium Aluminum Hydride-->3-Chloroperoxybenzoic acid-->ETHYLENEDIAMINE TETRAKIS(PROPOXYLATE-BLOCK-ETHOXYLATE) TETROL-->4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride